pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Company profile
Ticker
SUPN
Exchange
Website
CEO
Jack Khattar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SUPERNUS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
MDD US Enterprises, LLC • MDD US Operations, LLC • Supernus Europe Ltd. • Adamas Pharmaceuticals, LLC • Adamas Operations, LLC • Adamas Holdings, LLC • Biscayne Neurotherapeutics, Inc. ...
SUPN stock data
Latest filings (excl ownership)
8-K
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
23 May 24
8-K
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
9 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Supernus Announces First Quarter 2024 Financial Results
8 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial
24 Apr 24
8-K
Departure of Directors or Certain Officers
24 Apr 24
8-K
Supernus Provides Regulatory Update for SPN-830
8 Apr 24
Transcripts
SUPN
Earnings call transcript
2024 Q1
8 May 24
SUPN
Earnings call transcript
2023 Q4
27 Feb 24
SUPN
Earnings call transcript
2023 Q3
8 Nov 23
SUPN
Earnings call transcript
2023 Q2
8 Aug 23
SUPN
Earnings call transcript
2023 Q2
8 Aug 23
SUPN
Earnings call transcript
2023 Q1
9 May 23
SUPN
Earnings call transcript
2022 Q4
28 Feb 23
SUPN
Earnings call transcript
2022 Q3
8 Nov 22
SUPN
Earnings call transcript
2022 Q2
7 Aug 22
SUPN
Earnings call transcript
2022 Q1
10 May 22
Latest ownership filings
4
Padmanabh P. Bhatt
25 Mar 24
4
Padmanabh P. Bhatt
22 Mar 24
4
Padmanabh P. Bhatt
21 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
4
Padmanabh P. Bhatt
15 Mar 24
4
Padmanabh P. Bhatt
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Frank Mottola
29 Feb 24
4
Jack A. Khattar
29 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 63.40 mm | 63.40 mm | 63.40 mm | 63.40 mm | 63.40 mm | 63.40 mm |
Cash burn (monthly) | 3.88 mm | 33.23 mm | 1.05 mm | 987.25 k | (no burn) | (no burn) |
Cash used (since last report) | 8.04 mm | 68.79 mm | 2.18 mm | 2.04 mm | n/a | n/a |
Cash remaining | 55.36 mm | -5.39 mm | 61.23 mm | 61.36 mm | n/a | n/a |
Runway (months of cash) | 14.3 | -0.2 | 58.3 | 62.1 | n/a | n/a |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 239 |
Opened positions | 84 |
Closed positions | 25 |
Increased positions | 51 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 1.71 tn |
Total shares | 55.76 mm |
Total puts | 61.20 k |
Total calls | 84.10 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 10.36 mm | $353.46 bn |
Vanguard | 6.21 mm | $211.71 bn |
Armistice Capital | 3.57 mm | $121.84 bn |
MCQEF Macquarie | 2.67 mm | $91.04 bn |
Dimensional Fund Advisors | 2.56 mm | $87.22 bn |
STT State Street | 2.04 mm | $69.54 bn |
Polar Capital | 1.94 mm | $66.19 bn |
Stephens Investment Management | 1.90 mm | $64.87 bn |
Loomis Sayles & Co L P | 1.60 mm | $54.49 mm |
GW&K Investment Management | 1.34 mm | $45.69 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 35.31 | 14,491 | 511.68 k | 8,570 |
21 Mar 24 | Padmanabh P. Bhatt | Common Stock | Option exercise | Acquire M | No | Yes | 25.3 | 14,491 | 366.62 k | 23,061 |
21 Mar 24 | Padmanabh P. Bhatt | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 25.3 | 14,491 | 366.62 k | 12,745 |
20 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 35.31 | 400 | 14.12 k | 8,570 |
20 Mar 24 | Padmanabh P. Bhatt | Common Stock | Option exercise | Acquire M | No | Yes | 25.3 | 400 | 10.12 k | 8,970 |
20 Mar 24 | Padmanabh P. Bhatt | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 25.3 | 400 | 10.12 k | 27,236 |
19 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 35.31 | 12,364 | 436.57 k | 8,570 |
19 Mar 24 | Padmanabh P. Bhatt | Common Stock | Option exercise | Acquire M | No | Yes | 25.3 | 12,364 | 312.81 k | 20,934 |
19 Mar 24 | Padmanabh P. Bhatt | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 25.3 | 12,364 | 312.81 k | 27,636 |
13 Mar 24 | Padmanabh P. Bhatt | Common Stock | Sell | Dispose S | No | Yes | 33.48 | 36,116 | 1.21 mm | 8,570 |
News
Supernus Pharmaceuticals Q1 Sales $143.600M Miss $145.832M Estimate
8 May 24
M8 Pharmaceuticals Signs An Exclusive Licensing Agreement With Supernus Pharmaceuticals To Seek Regulatory Approval And Commercialize Qelbree Under M8's Trademark In Latin America
7 May 24
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
8 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Apr 24
Supernus Provides Regulatory Update For SPN-830, FDA Has Issued A CRL In Response To The Co's NDA For Spn-830 Indicating That The Review Cycle For The Application Is Complete, But That The Application Is Not Ready For Approval In Its Present Form.
8 Apr 24
Press releases
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
30 May 24
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
23 May 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
23 May 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
21 May 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
16 May 24